ALDH1L1 (Aldehyde Dehydrogenase 1 Family Member L1) is a cytosolic enzyme involved in folate metabolism, specifically catalyzing the conversion of 10-formyltetrahydrofolate to tetrahydrofolate and CO₂, a critical step in nucleotide synthesis. It is highly expressed in metabolically active tissues, including the liver, kidney, and brain, where it regulates cellular folate homeostasis and redox balance. Structurally, ALDH1L1 contains a formyltransferase domain, an NADP⁺-binding domain, and a hydrolase domain, enabling its multifunctional role. Dysregulation of ALDH1L1 has been linked to cancer, neurodegenerative disorders, and metabolic diseases, with its downregulation observed in various tumors, suggesting potential tumor-suppressive properties.
ALDH1L1 antibodies are essential tools for studying its expression, localization, and function in biological systems. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect ALDH1L1 protein levels in tissues or cell lines. In cancer research, ALDH1L1 antibodies help identify its loss as a biomarker for tumor progression or poor prognosis. In neuroscience, they aid in characterizing astrocyte populations, as ALDH1L1 is a recognized marker of differentiated astrocytes. Both polyclonal and monoclonal antibodies are available, with validation emphasizing specificity across human, mouse, and rat models. Their applications extend to exploring ALDH1L1’s role in oxidative stress response, one-carbon metabolism, and cellular differentiation, making them valuable in diverse biomedical research contexts.